Observational studyThe journals of gerontology. Series A, Biological sciences and medical sciences2025
Longitudinal associations between medication use and phenotypic aging: insights from the Baltimore longitudinal study of aging.
Observational study in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLimited population-based data exist on the association between medication use and changes in phenotypic aging. This study investigated these associations using data from the Baltimore Longitudinal Study of Aging.
methodsPhenotypic aging (PA) markers were constructed using the Klemera-Doubal method across four domains: body composition (structural and metabolic changes), energetics (energy generation and utilization capacity), homeostatic mechanisms (internal stability maintenance), and neuroplasticity/neurodegeneration (nervous system function and decline). Associations between 27 common drug categories and changes in these PA markers were analyzed using conditional generalized estimating equations (cGEE), focusing on within-individual variation to control for genetics and early-life factors, with additional adjustments for time-varying covariates.
resultsFive drug categories were associated with significant reductions in PA markers. Vitamin D, bisphosphonates, and proton pump inhibitors were linked to decreases in body composition (Beta = -0.73 years, 95% CI: -1.35 to -0.10), energetics (Beta = -2.05, 95% CI: -3.98 to -0.13), and neuroplasticity/neurodegeneration (Beta = -1.00, 95% CI: -2.02 to -0.03), respectively. Thyroid hormones showed reductions in body composition (Beta = -1.75, 95% CI: -3.24 to -0.26) and neuroplasticity/neurodegeneration (Beta = -1.04, 95% CI: -1.96 to -0.12). Thiazides were associated with decreases across body composition (Beta = -1.55, 95% CI: -2.94 to -0.16), energetics (Beta = -2.36, 95% CI: -4.30 to -0.42), and homeostatic mechanisms (Beta = -3.83, 95% CI: -6.71 to -0.96).
conclusionsThese findings suggest potential protective effects of certain medications on phenotypic aging. Further research is needed to validate these results, particularly with data from other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.